MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MannKind(MNKD) Newsfilter·2024-12-16 19:05MannKind(MNKD) Newsfilter·2024-12-16 19:05
R1MannKind(MNKD) Newsfilter·2024-12-16 19:05